{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:15Z","timestamp":1794047355526,"version":"4.8.0"},"reference-count":47,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"5","license":[{"start":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T00:00:00Z","timestamp":1586390400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Mantle cell lymphoma (MCL) with MYC rearrangement (MYC-R) is rare and little is known about the importance of MYC extra copies (EC) in the absence of MYC-R in MCL patients. This study includes 88 MCL patients with MYC tested by fluorescence in situ hybridization and\/or conventional cytogenetics, including 27 with MYC-R, 21 with MYC-EC, and 40 with normal (NL) MYC. MCL patients with MYC-R more often had blastoid\/pleomorphic morphology; a higher frequency of CD10, MYC, and simultaneous MYC and BCL2 expression; a higher level of MYC; and a higher Ki67 proliferation rate (p&lt;0.05) than those without MYC-R. Although patients with MYC-R more frequently received aggressive chemotherapy (p=0.001), their overall survival (OS) was significantly shorter than those without MYC-R. Compared with patients with MYC\/BCL2 double hit lymphoma (DHL), patients with MYC-R MCL had a similar OS but more commonly had bone marrow involvement, stage 4 disease, and a different immunophenotype. MCL patients with MYC-EC showed an OS intermediate between those with MYC-R and MYC-NL, either all or only blastoid\/pleomorphic MCL patients included. Multivariate analysis showed that MYC-R, but not MYC-EC, had an independent and negative impact on OS. In conclusion, MYC-R but not MYC-EC showed a higher MYC expression and is an adverse prognostic factor for MCL patients. Although the OS of MCL patients with MYC-R is similar to that of MYC\/BCL2 DHL patients, these groups have different clinicopathologic features supporting the retention of MCL with MYC-R in the category of MCL, as recommended in the revised World Health Organization classification.<\/jats:p>","DOI":"10.3324\/haematol.2019.243071","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T16:14:26Z","timestamp":1586448866000},"page":"1381-1389","source":"Crossref","is-referenced-by-count":31,"title":["&lt;i&gt;MYC&lt;\/i&gt; rearrangement but not extra &lt;i&gt;MYC&lt;\/i&gt; copies is an independent prognostic factor in patients with mantle cell lymphoma"],"prefix":"10.3324","volume":"106","author":[{"family":"Lifu Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Guilin Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"L. Jeffrey Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Jie Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Wenting Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"C. Cameron Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Michael Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Preetesh Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Pei Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Shaoying Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2020,4,9]]},"reference":[{"key":"25073","doi-asserted-by":"crossref","unstructured":"Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012; 122(10):3416-3423.","DOI":"10.1172\/JCI61272"},{"key":"25074","doi-asserted-by":"crossref","unstructured":"Vose JM. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2017; 92(8):806-813.","DOI":"10.1002\/ajh.24797"},{"key":"25075","doi-asserted-by":"crossref","unstructured":"AMaddocks K. Update on mantle cell lymphoma. Blood. 2018; 132(16):1647-1656.","DOI":"10.1182\/blood-2018-03-791392"},{"key":"25076","doi-asserted-by":"crossref","unstructured":"Sander B, Quintanilla-Martinez L, Ott G, Xerri L, Kuzu I, Chan JK. Mantle cell lymphoma--a spectrum from indolent to aggressive disease. Virchows Arch. 2016; 468(3):245-257.","DOI":"10.1007\/s00428-015-1840-6"},{"key":"25077","doi-asserted-by":"crossref","unstructured":"Lovec H, Grzeschiczek A, Kowalski MB, Moroy T. Cyclin D1\/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J. 1994; 13(15):3487-3495.","DOI":"10.1002\/j.1460-2075.1994.tb06655.x"},{"key":"25078","doi-asserted-by":"crossref","unstructured":"Hao S, Sanger W, Onciu M, Lai R, Schlette EJ, Medeiros LJ. Mantle cell lymphoma with 8q24 chromosomal abnormalities: a report of 5 cases with blastoid features. Mod Pathol. 2002; 15(12):1266-1272.","DOI":"10.1097\/01.MP.0000037310.82136.99"},{"key":"25079","doi-asserted-by":"crossref","unstructured":"Onciu M, Schlette E, Medeiros LJ, Abruzzo LV, Keating M, Lai R. Cytogenetic findings in mantle cell lymphoma cases with a high level of peripheral blood involvement have a distinct pattern of abnormalities. Am J Clin Pathol. 2001; 116(6):886-892.","DOI":"10.1309\/JQMR-323G-71Y9-M7MB"},{"key":"25080","doi-asserted-by":"crossref","unstructured":"Klapproth K, Wirth T. Advances in the understanding of MYC-induced lymphomagenesis. Br J Haematol. 2010; 149(4):484-497.","DOI":"10.1111\/j.1365-2141.2010.08159.x"},{"key":"25081","doi-asserted-by":"crossref","unstructured":"Sewastianik T, Prochorec-Sobieszek M, Chapuy B, Juszczynski P. MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications. Biochim Biophys Acta. 2014; 1846(2):457-467.","DOI":"10.1016\/j.bbcan.2014.08.006"},{"key":"25082","unstructured":"Kluin PM, Harris NL, Stein H. Highgrade B-cell lymphoma. 2017;335-341."},{"key":"25083","unstructured":"Swerdlow SH, Campo E, Seto M, and Muller-Hermelink H.K. Mantle cell lymphoma. Lyon, France: IARC. 2017."},{"key":"25084","doi-asserted-by":"crossref","unstructured":"Lin P, Dickason TJ, Fayad LE. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Cancer. 2012; 118(6):1566-1573.","DOI":"10.1002\/cncr.26433"},{"key":"25085","doi-asserted-by":"crossref","unstructured":"Landsburg DJ, Falkiewicz MK, Maly J. Outcomes of patients with double-hit lymphoma who achieve first complete remission. J Clin Oncol. 2017; 35(20):2260-2267.","DOI":"10.1200\/JCO.2017.72.2157"},{"key":"25086","doi-asserted-by":"crossref","unstructured":"Li S, Lin P, Fayad LE. B-cell lymphomas with MYC\/8q24 rearrangements and IGH@BCL2\/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol. 2012; 25(1):145-156.","DOI":"10.1038\/modpathol.2011.147"},{"key":"25087","doi-asserted-by":"crossref","unstructured":"Li S, Saksena A, Desai P. Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC\/BCL2 double hit lymphoma. Oncotarget. 2016; 7(25):38122-38132.","DOI":"10.18632\/oncotarget.9473"},{"key":"25088","doi-asserted-by":"crossref","unstructured":"Li S, Seegmiller AC, Lin P. B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC\/BCL2 double-hit lymphomas. Mod Pathol. 2015; 28(2):208-217.","DOI":"10.1038\/modpathol.2014.95"},{"key":"25089","doi-asserted-by":"crossref","unstructured":"Li S, Huang W, Oki Y, Medeiros JL. MYC\/BCL2\/BCL6 triple hit lymphoma: A study of 33 patients who had an aggressive clinical course similar to patients with double hit lymphomas. J Clin Oncol. 2017; 35:7559.","DOI":"10.1200\/JCO.2017.35.15_suppl.7559"},{"key":"25090","doi-asserted-by":"crossref","unstructured":"Petrich AM, Gandhi M, Jovanovic B. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014; 124(15):2354-2361.","DOI":"10.1182\/blood-2014-05-578963"},{"key":"25091","doi-asserted-by":"crossref","unstructured":"Ott G, Rosenwald A, Campo E. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Blood. 2013; 122(24):3884-3891.","DOI":"10.1182\/blood-2013-05-498329"},{"key":"25092","doi-asserted-by":"crossref","unstructured":"Aukema SM, Siebert R, Schuuring E. Double-hit B-cell lymphomas. Blood. 2011; 117(8):2319-2331.","DOI":"10.1182\/blood-2010-09-297879"},{"key":"25093","doi-asserted-by":"crossref","unstructured":"Li S, Desai P, Lin P. MYC\/BCL6 double- hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis. Histopathology. 2016; 68(7):1090-1098.","DOI":"10.1111\/his.12884"},{"key":"25094","doi-asserted-by":"crossref","unstructured":"Landsburg DJ, Petrich AM, Abramson JS. Impact of oncogene rearrangement patterns on outcomes in patients with doublehit non-Hodgkin lymphoma. Cancer. 2016; 122(4):559-564.","DOI":"10.1002\/cncr.29781"},{"key":"25095","unstructured":"Kluin PM., Campo E, Harris NL, Jaffe ES. High Grade B-Cell Lymphoma. 2017."},{"key":"25096","unstructured":"Au WY, Horsman DE, Viswanatha DS, Connors JM, Klasa RJ, Gascoyne RD. 8q24 translocations in blastic transformation of mantle cell lymphoma. Haematologica. 2000; 85(11):1225-1227."},{"key":"25097","doi-asserted-by":"crossref","unstructured":"Delas A, Sophie D, Brousset P, Laurent C. Unusual concomitant rearrangements of Cyclin D1 and MYC genes in blastoid variant of mantle cell lymphoma: case report and review of literature. Pathol Res Pract. 2013; 209(2):115-119.","DOI":"10.1016\/j.prp.2012.12.001"},{"key":"25098","doi-asserted-by":"crossref","unstructured":"Hu Z, Medeiros LJ, Chen Z. Mantle cell Lymphoma with MYC rearrangement: a report of 17 patients. Am J Surg Pathol. 2017; 41(2):216-224.","DOI":"10.1097\/PAS.0000000000000758"},{"key":"25099","doi-asserted-by":"crossref","unstructured":"Reddy K, Ansari-Lari M, Dipasquale B. Blastic mantle cell lymphoma with a Burkitt translocation. Leuk Lymphoma. 2008; 49(4):740-750.","DOI":"10.1080\/10428190701852024"},{"key":"25100","unstructured":"Setoodeh R, Schwartz S, Papenhausen P. Double-hit mantle cell lymphoma with MYC gene rearrangement or amplification: a report of four cases and review of the literature. Int J Clin Exp Pathol. 2013; 6(2):155-167."},{"key":"25101","doi-asserted-by":"crossref","unstructured":"Xu J, Li S. Triple-hit blastoid mantle cell lymphoma presenting like acute leukemia. Blood. 2017; 129(18):2593.","DOI":"10.1182\/blood-2017-02-770503"},{"key":"25102","doi-asserted-by":"crossref","unstructured":"Hans CP, Weisenburger DD, Greiner TC. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103(1):275-282.","DOI":"10.1182\/blood-2003-05-1545"},{"key":"25103","doi-asserted-by":"crossref","unstructured":"Slotta-Huspenina J, Koch I, de Leval L. The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index. Haematologica. 2012; 97(9):1422-1430.","DOI":"10.3324\/haematol.2011.055715"},{"key":"25104","doi-asserted-by":"crossref","unstructured":"Visco C, Tzankov A, Xu-Monette ZY. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica. 2013; 98(2):255-263.","DOI":"10.3324\/haematol.2012.066209"},{"key":"25105","doi-asserted-by":"crossref","unstructured":"Ribera-Cortada I, Martinez D, Amador V. Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype. Mod Pathol. 2015; 28(11):1435-1447.","DOI":"10.1038\/modpathol.2015.99"},{"key":"25106","doi-asserted-by":"crossref","unstructured":"Saksena A, Yin CC, Xu J. CD23 expression in mantle cell lymphoma is associated with CD200 expression, leukemic non-nodal form, and a better prognosis. Hum Pathol. 2019; 89:71-80.","DOI":"10.1016\/j.humpath.2019.04.010"},{"key":"25107","doi-asserted-by":"crossref","unstructured":"Huang W, Medeiros LJ, Lin P. MYC\/BCL2\/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC\/BCL2 and MYC\/BCL6 double hit lymphomas. Mod Pathol. 2018; 31(9):1470-1478.","DOI":"10.1038\/s41379-018-0067-x"},{"key":"25108","doi-asserted-by":"crossref","unstructured":"McGowan-Jordan J, Simons A, Schmid M. An International System for Human Cytogenetic Nomenclature (ISCN 2016), Recommendations of the International Standing Commitee on Human Cytogenetic Nomenclature. Unionville, USA: Karger. 2016.","DOI":"10.1159\/isbn.978-3-318-06861-0"},{"key":"25109","doi-asserted-by":"crossref","unstructured":"Hoster E, Dreyling M, Klapper W. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008; 111(12):558-565.","DOI":"10.1182\/blood-2007-06-095331"},{"key":"25110","doi-asserted-by":"crossref","unstructured":"Zhou J, Hu L, Zuo M, Zhou Y, Li G, Zhang X. An uncommon case of double-hit mantle cell lymphoma that demonstrates a transformation process. Am J Clin Pathol. 2019; 153(1):49-57.","DOI":"10.1093\/ajcp\/aqz133"},{"key":"25111","doi-asserted-by":"crossref","unstructured":"Vincent-Fabert C, Fiancette R, Rouaud P. A defect of the INK4-Cdk4 checkpoint and Myc collaborate in blastoid mantle cell lymphoma-like lymphoma formation in mice. Am J Pathol. 2012; 180(4):1688-1701.","DOI":"10.1016\/j.ajpath.2012.01.004"},{"key":"25112","doi-asserted-by":"crossref","unstructured":"Lee J, Zhang LL, Wu W. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma. Blood Adv. 2018; 2(16):2039-2051.","DOI":"10.1182\/bloodadvances.2018016048"},{"key":"25113","doi-asserted-by":"crossref","unstructured":"Zhang X, Chen X, Lin J. Myc represses miR-15a\/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene. 2012; 31(24):3002-3008.","DOI":"10.1038\/onc.2011.470"},{"key":"25114","doi-asserted-by":"crossref","unstructured":"Chisholm KM, Bangs CD, Bacchi CE, Molina-Kirsch H, Cherry A, Natkunam Y. Expression profiles of MYC protein and MYC gene rearrangement in lymphomas. Am J Surg Pathol. 2015; 39(3):294-303.","DOI":"10.1097\/PAS.0000000000000365"},{"key":"25115","doi-asserted-by":"crossref","unstructured":"Oberley MJ, Rajguru SA, Zhang C. Immunohistochemical evaluation of MYC expression in mantle cell lymphoma. Histopathology. 2013; 63(4):499-508.","DOI":"10.1111\/his.12207"},{"key":"25116","doi-asserted-by":"crossref","unstructured":"Wang XJ, Medeiros LJ, Lin P. MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC\/BCL2 protein doublepositive diffuse large B-cell lymphoma. Am J Surg Pathol. 2015; 39(9):1250-1258.","DOI":"10.1097\/PAS.0000000000000433"},{"key":"25117","doi-asserted-by":"crossref","unstructured":"Miao Y, Lin P, Wang W, Jeffrey Medeiros L, Lu X. CCND1-IGH Fusion-Amplification and MYC Copy Number Gain in a Case of Pleomorphic Variant Mantle Cell Lymphoma. Am J Clin Pathol. 2016; 146(6):747-752.","DOI":"10.1093\/ajcp\/aqw194"},{"key":"25118","doi-asserted-by":"crossref","unstructured":"Yi S, Zou D, Li C. High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival. Oncotarget. 2015; 6(39):42362-42371.","DOI":"10.18632\/oncotarget.5705"},{"key":"25119","doi-asserted-by":"crossref","unstructured":"Quesada AE, Medeiros LJ, Desai PA. Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma. Mod Pathol. 2017; 30(12):1688-1697.","DOI":"10.1038\/modpathol.2017.93"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/9709\/70748","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9709\/70749","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9709\/70748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:56:44Z","timestamp":1794045404000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/9709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,9]]},"references-count":47,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,4,30]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2019.243071","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,9]]}}}